Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients

Research output: Contribution to journalArticle

Abstract

First anti-HCV treatments, that include protease inhibitors in conjunction with IFN-α and Ribavirin, increase the sustained virological response (SVR) up to 80% in patients infected with HCV genotype 1. The effects of triple therapies on dendritic cell (DC) compartment have not been investigated. In this study we evaluated the effect of telaprevir-based triple therapy on DC phenotype and function, and their possible association with treatment outcome. HCV+ patients eligible for telaprevir-based therapy were enrolled, and circulating DC frequency, phenotype, and function were evaluated by flow-cytometry. The antiviral activity of plasmacytoid DC was also tested. In SVR patients, myeloid DC frequency transiently decreased, and returned to baseline level when telaprevir was stopped. Moreover, an up-regulation of CD80 and CD86 on mDC was observed in SVR patients as well as an improvement of IFN-α production by plasmacytoid DC, able to inhibit in vitro HCV replication.

Original languageEnglish
Pages (from-to)82-90
Number of pages9
JournalClinical Immunology
Volume183
DOIs
Publication statusPublished - Oct 1 2017

Keywords

  • Dendritic cells
  • Directly acting antivirals
  • HCV
  • IFN-α
  • T cells

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients'. Together they form a unique fingerprint.

  • Cite this